Effect of Chronic Administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone Mesylate (WIN55,212-2) or Δ9-Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in Mice
Open Access
- 1 January 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 303 (1) , 36-44
Abstract
Agonist efficacy may influence the magnitude of neuroadaptation in response to chronic drug exposure. Chronic administration of either Δ9-tetrahydrocannabinol (THC), a partial agonist, orR-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo-[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2), a full agonist, for G protein activation produces tolerance to cannabinoid-mediated behaviors. The present study examined whether chronic administration of maximally tolerated doses of Δ9-THC and WIN55,212-2 produces similar cannabinoid receptor desensitization and down-regulation. Mice were treated with escalating doses of agonist for 15 days, with final doses of 160 mg/kg Δ9-THC and 48 mg/kg WIN55,212-2. Tolerance to cannabinoid-mediated hypoactivity, hypothermia, and antinociception was found after treatment with Δ9-THC or WIN55,212-2. In autoradiographic studies, cannabinoid-stimulated guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding was significantly decreased in all regions of Δ9-THC- and WIN55,212-2-treated brains. In addition, Δ9-THC-treated brains showed greater desensitization in some regions than WIN55,212-2-treated brains. Concentration-effect curves for cannabinoid-stimulated [35S]GTPγS binding confirmed that decreases in the hippocampus resulted from loss of maximal effect in both WIN55,212-2- and Δ9-THC-treated mice. In the substantia nigra, theEmax decreased and the EC50value increased for agonist stimulation of [35S]GTPγS binding in Δ9-THC-treated mice. [3H]N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) binding was decreased in all brain regions in Δ9-THC- and WIN55,212-2-treated mice, with no difference between treatment groups. These results demonstrate that chronic treatment with either the partial agonist Δ9-THC or the full agonist WIN55,212-2 produces tolerance to cannabinoid-mediated behaviors, as well as cannabinoid receptor desensitization and down-regulation. Furthermore, Δ9-THC produced greater desensitization than WIN55,212-2 in some regions, indicating that agonist efficacy is one determinant of cannabinoid receptor desensitization in brain.Keywords
This publication has 41 references indexed in Scilit:
- Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse BrainMolecular Pharmacology, 2001
- μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependenceNature, 2000
- Time course for the induction and maintenance of tolerance to Δ9-tetrahydrocannabinol in miceDrug and Alcohol Dependence, 2000
- Agonist Selective Regulation of G Proteins by Cannabinoid CB1and CB2ReceptorsMolecular Pharmacology, 1999
- Chronic ▵9‐Tetrahydrocannabinol Treatment Produces a Time‐Dependent Loss of Cannabinoid Receptors and Cannabinoid Receptor‐Activated G Proteins in Rat BrainJournal of Neurochemistry, 1999
- Distribution of heterotrimeric G-protein β and γ subunits in the rat brainNeuroscience, 1998
- Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant miceBrain Research, 1996
- The Effect of Intrinsic Efficacy on Opioid ToleranceAnesthesiology, 1995
- Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic studyThe Journal of Neuroscience, 1991
- Tolerance to Chronic Administration of Cannabis sativa (Marihuana) in RatsPharmacology, 1968